Clinical Data Beam one-ups Wave as both show promise of genetic editing for AATD BioSpaceWhile both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets,...Rare DiseaseRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets,… Rare Disease Read full story Post navigation Previous: Parabilis follows hefty Regeneron deal with IPO pushNext: Pepaxti study supports use in wider myeloma population Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
